Gilead Sciences, Inc (GILD) concluded trading on Thursday at a closing price of $91.88, with 3.29 million shares of worth about $301.91 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 37.98% during that period and on Thursday the price saw a loss of about -0.53%. Currently the company’s common shares owned by public are about 1.25B shares, out of which, 1.24B shares are available for trading.
Stock saw a price change of -2.20% in past 5 days and over the past one month there was a price change of -2.28%. Year-to-date (YTD), GILD shares are showing a performance of -0.53% which increased to 10.38% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $62.07 but also hit the highest price of $98.90 during that period. The average intraday trading volume for Gilead Sciences, Inc shares is 6.39 million. The stock is currently trading -0.56% below its 20-day simple moving average (SMA20), while that difference is up 0.45% for SMA50 and it goes to 18.35% higher than SMA200.
Gilead Sciences, Inc (NASDAQ: GILD) currently have 1.25B outstanding shares and institutions hold larger chunk of about 85.33% of that.
The stock has a current market capitalization of $114.51B and its 3Y-monthly beta is at 0.20. PE ratio of stock for trailing 12 months is 1035.85, while it has posted earnings per share of $0.09 in the same period. Its PEG reads 110.69 and has Quick Ratio of 1.10 while making debt-to-equity ratio of 1.26. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for GILD, volatility over the week remained 1.61% while standing at 2.18% over the month.
Stock’s fiscal year EPS is expected to drop by -34.72% while it is estimated to increase by 72.59% in next year. EPS is likely to grow at an annualized rate of 9.36% for next 5-years, compared to annual growth of 1.55% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BofA Securities on December 10, 2024 offering a Buy rating for the stock and assigned a target price of $109 to it. Coverage by Wolfe Research stated Gilead Sciences, Inc (GILD) stock as an Outperform in their note to investors on November 15, 2024, suggesting a price target of $110 for the stock. Stock get an Outperform rating from Leerink Partners on October 21, 2024.
